Transactions
24
Insider / Vaxcyte, Inc.
Cowan Elvia
SVP, Finance & CAO at Vaxcyte, Inc.
- Company
- Vaxcyte, Inc.
- Ticker
- PCVX
- First filing on record
- December 29, 2025
- Latest trade on record
- October 5, 2026
- SEC filings
- EDGAR ↗
Cowan Elvia, SVP, Finance & CAO at Vaxcyte, Inc., has disclosed 24 transactions in PCVX since December 29, 2025: 0 purchases (0 open-market buys) and 13 sales, worth about $3.7M at the reported prices. The latest was filed October 7, 2026, 2 days after the trade; 3 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
13
Avg. disclosure lag
2.2d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Cowan Elvia made no purchases and 13 sales worth $2.8M, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Cowan Elvia has traded 1 stock on record; the largest by dollars is PCVX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 8 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 64,432 | $835K |
| S | Open-market sale | 7 | 38,015 | $2.6M |
| F | Shares withheld for tax | 6 | 2,960 | $180K |
| A | Grant or award | 2 | 28,536 | — |
| G | Gift | 1 | 1,000 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 21 | 0 | 11 · $2.3M |
| 2025 | 3 | 0 | 2 · $557K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | Option / conversion M | October 5, 2026 | October 7, 2026 | 2d | 19,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| PCVX | Sell S | October 5, 2026 | October 7, 2026 | 2d | 19,000 | $87 | $1.6M | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Option / conversion M | October 5, 2026 | October 7, 2026 | 2d | 19,000 | $26 | $492K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Sell F | September 8, 2026 | September 9, 2026 | 1d | 1,327 | $60 | $80K | Form 4 ↗ | ||
| PCVX | Sell F | September 2, 2026 | September 2, 2026 | 0d | 326 | $62 | $20K | Form 4 ↗ | ||
| PCVX | Sell F | August 31, 2026 | September 2, 2026 | 2d | 243 | $61 | $15K | Form 4 ↗ | ||
| PCVX | Option / conversion M | April 7, 2026 | April 8, 2026 | 1d | 3,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| PCVX | Sell S | April 7, 2026 | April 8, 2026 | 1d | 3,000 | $60 | $180K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Option / conversion M | April 7, 2026 | April 8, 2026 | 1d | 3,000 | $26 | $78K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Sell S | March 17, 2026 | March 18, 2026 | 1d | 405 | $56 | $23K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Sell S | March 17, 2026 | March 18, 2026 | 1d | 1,487 | $55 | $82K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Option / conversion M | March 11, 2026 | March 11, 2026 | 0d | 2,500 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| PCVX | Sell S | March 11, 2026 | March 11, 2026 | 0d | 2,500 | $59 | $146K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Option / conversion M | March 11, 2026 | March 11, 2026 | 0d | 2,500 | $26 | $65K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Sell F | March 9, 2026 | March 11, 2026 | 2d | 495 | $59 | $29K | 10b5-1 plan | Form 4 ↗ | |
| PCVX | Option / conversion M | February 26, 2026 | March 2, 2026 | 4d | 7,716 | — | — | derivative | Form 4 ↗ | |
| PCVX | Other A | February 26, 2026 | March 2, 2026 | 4d | 17,855 | — | — | derivative | Form 4 ↗ | |
| PCVX | Sell F | March 2, 2026 | March 2, 2026 | 0d | 326 | $62 | $20K | Form 4 ↗ | ||
| PCVX | Sell F | February 28, 2026 | March 2, 2026 | 2d | 243 | $62 | $15K | Form 4 ↗ | ||
| PCVX | Option / conversion M | February 26, 2026 | March 2, 2026 | 4d | 7,716 | $26 | $200K | Form 4 ↗ | ||
| PCVX | Other A | February 26, 2026 | March 2, 2026 | 4d | 10,681 | — | — | Form 4 ↗ | ||
| PCVX | Other G | December 23, 2025 | December 29, 2025 | 6d | 1,000 | — | — | late | Form 4 ↗ | |
| PCVX | Sell S | December 23, 2025 | December 29, 2025 | 6d | 6,716 | $48 | $322K | late | Form 4 ↗ | |
| PCVX | Sell S | December 23, 2025 | December 29, 2025 | 6d | 4,907 | $48 | $235K | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 7, 2026 | Form 4 | 0001960048-26-000013 | 3 | published | EDGAR ↗ |
| September 9, 2026 | Form 4 | 0001960048-26-000011 | 1 | published | EDGAR ↗ |
| September 2, 2026 | Form 4 | 0001960048-26-000009 | 2 | published | EDGAR ↗ |
| April 8, 2026 | Form 4 | 0001960048-26-000007 | 3 | published | EDGAR ↗ |
| March 18, 2026 | Form 4 | 0001960048-26-000005 | 2 | published | EDGAR ↗ |
| March 11, 2026 | Form 4 | 0001960048-26-000004 | 4 | published | EDGAR ↗ |
| March 2, 2026 | Form 4 | 0001960048-26-000002 | 6 | published | EDGAR ↗ |
| December 29, 2025 | Form 4 | 0001960048-25-000010 | 3 | published | EDGAR ↗ |
Other insiders at Vaxcyte, Inc.
- Wassil Jim CHIEF OPERATING OFFICER 41 rows
- PICKERING GRANT CHIEF EXECUTIVE OFFICER 32 rows
- GUGGENHIME ANDREW PRESIDENT AND CFO 21 rows
- Dhaliwal Harpreet S. Chief Technical Ops Officer 12 rows
- Gilbert Halley E Director 7 rows
- BRANDICOURT OLIVIER Director 6 rows
- Drapeau Anne S Director 2 rows
- Furey John Director 2 rows
- Jodar Luis Chief Medical Officer 2 rows
- Lee Jacks Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: Vaxcyte, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 8 | 24 | December 29, 2025 | October 7, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.